Expression of EGFR, PD‐L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high‐grade serous tubo‐ovarian carcinoma

Author:

Nikas Ilias P.1ORCID,Park Soo‐Young23,Song Min Ji2,Lee Cheol2,Ryu Han Suk23ORCID

Affiliation:

1. School of Medicine European University Cyprus Nicosia Cyprus

2. Department of Pathology Seoul National University Hospital Seoul Republic of Korea

3. Department of Pathology Seoul National University College of Medicine Seoul Republic of Korea

Abstract

AbstractAimTo compare the immunochemical expression of EGFR, PD‐L1, and the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6 between matched malignant effusions obtained before and following the administration of chemotherapy in patients with high‐grade serous tubo‐ovarian carcinoma (HGSC).MethodsIn the enrolled HGSCs, matched formalin‐fixed and paraffin‐embedded cell blocks (CBs) from effusions sampled before (treatment‐naïve patients) and during recurrence (following chemotherapy administration), in addition to their matched HGSC tissues obtained from the ovaries at initial diagnosis (treatment‐naïve patients), were subjected to EGFR, PD‐L1, and MMR immunochemical analysis.ResultsEGFR was more often overexpressed in effusions obtained after chemotherapy administration compared to both effusions (100% vs. 57.1%) and their matched tubo‐ovarian tumors (100% vs. 7.1%) from treatment‐naïve patients, respectively. EGFR immunochemistry was concordant in just 9.1% of the effusions sampled during recurrence and their paired ovarian samples before recurrence. Whereas all HGSC treatment‐naïve samples (ovarian lesions and effusions) were PD‐L1 negative, 3/11 (27.3%) malignant effusions obtained during recurrence showed PD‐L1 overexpression. Lastly, none of the tested HGSC samples exhibited MMR deficiency.ConclusionMeasuring biomarkers using CBs from malignant effusions may provide clinicians with significant information related to HGSC prognosis and therapy selection, especially in patients with resistance to chemotherapy.

Funder

National Research Foundation of Korea

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3